The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of
pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in …

PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to
adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The diagnosis and treatment of invasive breast cancer requires a collaborative effort among
multiple subspecialties. Diagnostic imaging workup and biopsy play a key role in …